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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
soy isoflavones and protection of DNA, proteins and lipids from oxidative 
damage (ID 1286, 4245), maintenance of normal blood LDL-cholesterol 
concentrations (ID 1135, 1704a, 3093a), reduction of vasomotor symptoms 
associated with menopause (ID 1654, 1704b, 2140, 3093b, 3154, 3590), 
maintenance of normal skin tonicity (ID 1704a), contribution to normal 
hair growth (ID 1704a, 4254), “cardiovascular health” (ID 3587), treatment 
of prostate cancer (ID 3588) and “upper respiratory tract” (ID 3589) 
pursuant to Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to soy isoflavones and protection of DNA, proteins and lipids from oxidative damage, 
maintenance of normal blood LDL-cholesterol concentrations, reduction of vasomotor symptoms 
associated with menopause, maintenance of normal skin tonicity, contribution to normal hair growth, 
“cardiovascular health”, treatment of prostate cancer, and “upper respiratory tract”. The scientific 
substantiation is based on the information provided by the Member States in the consolidated list of 
Article 13 health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1874, EFSA-Q-2008-2024, EFSA-Q-2008-2440, 
EFSA-Q-2008-3825, EFSA-Q-2008-4312, EFSA-Q-2008-4313, EFSA-Q-2008-4314, EFSA-Q-2008-4955, adopted on 
25 March 2011. Question No EFSA-Q-2008-4964, adopted on 08 April 2011. Question No EFSA-Q-2008-2390, EFSA-
Q-2008-05018, EFSA-Q-2008-2873, EFSA-Q-2008-05019, EFSA-Q-2008-3886, EFSA-Q-2008-4315, adopted on 
30 June 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims for the preparatory work on 
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Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. 
 
Soy isoflavones related health claims 
 
2 EFSA Journal 2011;9(7):2264 
The food constituent that is the subject of the health claims is soy isoflavones. The Panel considers 
that soy isoflavones are sufficiently characterised. 
Protection of DNA, proteins and lipids from oxidative damage 
The claimed effects are “vascular effects including protection from oxidative damage” and “antioxidant 
status”. The target population is assumed to be the general population. In the context of the proposed 
wordings, the Panel assumes that the claimed effects refer to the protection of body cells and 
molecules from oxidative damage. The Panel considers that protection of DNA, proteins and lipids 
from oxidative damage may be a beneficial physiological effect. 
No human studies from which conclusions could be drawn for the scientific substantiation of the 
claim were provided. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of soy isoflavones and protection of DNA, proteins and lipids from oxidative damage. 
Maintenance of normal blood LDL-cholesterol concentrations 
The claimed effects are “cholesterol management / heart health”, “menopause/skin and hair health 
during menopause/cholesterol management” and “act as phyto-estrogens”. The target population is 
assumed to be the general population. In the context of the proposed wordings and the clarifications 
provided by Member States, the Panel assumes that the claimed effects refer to the maintenance of 
normal blood LDL-cholesterol concentrations. The Panel considers that maintenance of normal blood 
LDL-cholesterol concentrations is a beneficial physiological effect. 
The Panel notes that one meta-analysis including nine RCTs, and three additional RCTs, did not show 
an effect of extracted soy isoflavones on blood LDL-cholesterol concentrations. The Panel also notes 
that out of the 23 human intervention studies in which soy isoflavones were consumed in soy protein 
from which conclusions could be drawn for the scientific substantiation of the claim, 14 studies 
(n=1,286 subjects, 12-93 subjects per group/period) with durations between one and 12 months using 
isoflavone doses of around 60-330 mg per day did not show an effect of soy isoflavones on blood 
cholesterol concentrations in subjects with slightly elevated or high blood LDL-cholesterol 
concentrations, whereas eight studies (n=712 subjects, 15-42 subjects per group/period) with 
durations between six weeks and six months using isoflavone doses of around 30-185 mg per day 
showed a statistically significant effect in subjects with normal to high blood LDL-cholesterol 
concentrations, and one study (n=94 subjects, around 30 per group) led to inconsistent results with 
respect to the effect of soy isoflavones on blood LDL-cholesterol concentrations. The Panel also notes 
that most of the studies had some methodological limitations, and that the inconsistent results reported 
appear unrelated to the dose of isoflavones used, the study duration, the sample size or the baseline 
characteristics of subjects with respect to blood cholesterol concentrations.  
In weighing the evidence, the Panel took into account that one meta-analysis of nine randomised 
controlled trials, and three additional randomised controlled trials, did not show an effect of extracted 
soy isoflavones on blood cholesterol concentrations, and that the evidence provided by 23 human 
randomised controlled trials in which soy isoflavones were consumed in soy protein is inconsistent.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of soy isoflavones and maintenance of normal blood LDL-cholesterol concentrations. 
Reduction of vasomotor symptoms associated with menopause  
The claimed effects are “menopause”, “menopause/skin and hair health during menopause/cholesterol 
management”, “soy contains the phytoestrogens isoflavones that can function as either an estrogen 
agonist or antagonist”, “act as phytoestrogens”, “helps to keep healthy thermoregulation during 
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climacterium”, and “helps to alleviate the symptoms of menopause”. The target population is assumed 
to be post-menopausal women. In the context of the proposed wordings and the clarifications 
provided by Member States, the Panel assumes that the claimed effects refer to the reduction of 
vasomotor symptoms associated with menopause. The Panel considers that reduction of vasomotor 
symptoms associated with menopause is a beneficial physiological effect. 
The Panel notes that from the 12 human intervention studies provided from which conclusions can be 
drawn for the scientific substantiation of the claim, most of which have some methodological 
limitations and/or inadequate reporting, five studies (n=498 subjects analysed; range: 25-115 per 
group) with a duration of 12 weeks to 12 months using doses from 27 mg genistein to 100 mg of total 
isoflavones showed a statistically significant effect of soy isoflavones on vasomotor symptoms after 
one month (one study), three months (two studies), four months (one study) and 10 months (one 
study), whereas six studies (n=463 subjects analysed, range: 12-99 per group/period) with a duration 
of six weeks to six months using doses from 40 mg to 118 mg of total isoflavones did not show a 
statistically significant effect of soy isoflavones on vasomotor symptoms, and that one study in 122 
analysed subjects using a dose of 50 mg isoflavones for four months led to inconsistent results with 
regard to the effect soy isoflavones on vasomotor symptoms. 
In weighing the evidence, the Panel took into account that the evidence provided by 12 human 
intervention studies is inconsistent with respect to the reduction of vasomotor symptoms, and that the 
inconsistent results cannot be explained by dose, sample size, study duration, or baseline frequency or 
severity of vasomotor symptoms.  
The Panel concludes that the evidence provided is insufficient to establish a cause and effect 
relationship between the consumption of soy isoflavones and reduction of vasomotor symptoms 
associated with menopause. 
Maintenance of normal skin tonicity 
The claimed effect is “menopause/skin and hair health during menopause/cholesterol management”. 
The target population is assumed to be post-menopausal women. In the context of the proposed 
wordings and the clarifications provided by Member States, the Panel assumes that the claimed effect 
refers to the maintenance of normal skin tonicity. No evidence has been provided on how skin tonicity 
could be related to skin function. 
The Panel considers that the claim does not refer to a function of the body as required by Regulation 
(EC) No 1924/2006. 
Contribution to normal hair growth 
The claimed effect is “menopause/skin and hair health during menopause/cholesterol management” 
and “hair growth and loss”. The target population is assumed to be the general population. In the 
context of the proposed wordings, the Panel assumes that the claimed effects refer to normal hair 
growth. The Panel considers that contribution to normal hair growth is a beneficial physiological 
effect. 
No references from which conclusions could be drawn for the scientific substantiation of the claim 
were provided. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of soy isoflavones and contribution to normal hair growth. 
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4 EFSA Journal 2011;9(7):2264 
“Cardiovascular health” 
The claimed effect is “contributes to cardiovascular health”. The target population is assumed to be 
the general population. The claimed effect is not sufficiently defined and no further details were 
provided in the proposed wordings. No clarifications were provided by Member States. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
Treatment of prostate cancer 
The claimed effect is “contributes to maintain a healthy prostate and breast”. The target population is 
assumed to be the general population. From the references provided, it is assumed that the claimed 
effect is related to the treatment of prostate cancer. 
The Panel considers that the claim is related to the treatment of disease and does not comply with the 
criteria laid down in Regulation (EC) No 1924/2006. 
“Upper respiratory tract” 
The claimed effect is “contributes to the upper respiratory tract health”. The target population is 
assumed to be the general population. The claimed effect is not sufficiently defined and no further 
details were provided in the proposed wordings. No clarifications were provided by Member States. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
KEY WORDS 
Soy isoflavones, oxidative damage, cholesterol, skin tonicity, hair growth, vasomotor symptoms, menopause, 
prostate cancer, cardiovascular health, upper respiratory tract, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claims is soy isoflavones.  
Soy isoflavones constitute a wide range of compounds of plant origin, which mainly comprise 
genistein, daidzein and glycitein, among others (Ma et al., 2008a, 2008b). Soy isoflavones can be 
consumed as isolated soybean protein (ISP), as whole-soybean foods or extracts, as supplements or as 
pure compounds (Cassidy et al., 2006).  
The Panel considers that the food constituent, soy isoflavones, which is the subject of the health 
claims, is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
2.1. Protection of DNA, proteins and lipids from oxidative damage (ID 1286, 4245) 
The claimed effects are “vascular effects including protection from oxidative damage” and “antioxidant 
status”. The Panel assumes that the target population is the general population. 
The Panel considers that claims made on the antioxidant capacity/content or properties of foods/food 
constituents based on their capability to scavenge free radicals in vitro refer to a property of the 
foods/food constituents measured in model systems, and that the information provided does not 
establish that this capability exerts a beneficial physiological effect in humans as required by 
Regulation (EC) No 1924/2006. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
protection of body cells and molecules from oxidative damage caused by free radicals.  
Reactive oxygen species (ROS) including several kinds of radicals are generated in biochemical 
processes (e.g. respiratory chain) and as a consequence of exposure to exogenous factors 
(e.g. radiation and pollutants). These reactive intermediates can damage molecules such as DNA, 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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proteins and lipids if they are not intercepted by the antioxidant network which includes free radical 
scavengers such as antioxidant nutrients. 
The Panel considers that protection of DNA, proteins and lipids from oxidative damage may be a 
beneficial physiological effect. 
2.2. Maintenance of normal blood LDL-cholesterol concentrations (ID 1135, 1704a, 3093a) 
The claimed effects are “cholesterol management / heart health”, “menopause/skin and hair health 
during menopause/cholesterol management” and “act as phyto-estrogens”. The Panel assumes that the 
target population is the general population.  
In the context of the proposed wordings and the clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to the maintenance of normal blood LDL-cholesterol 
concentrations.  
Low-density lipoproteins (LDL) carry cholesterol from the liver to peripheral tissues, including the 
arteries. Elevated LDL-cholesterol, by convention >160 mg/dL (>4.1 mmol/L), may compromise the 
normal structure and function of the arteries. 
The Panel considers that maintenance of normal blood LDL-cholesterol concentrations is a beneficial 
physiological effect. 
2.3. Reduction of vasomotor symptoms associated with menopause (ID 1654, 1704b, 2140, 
3093b, 3154, 3590) 
The claimed effects are “menopause”, “menopause/skin and hair health during menopause/cholesterol 
management”, “soy contains the phytoestrogens isoflavones that can function as either an estrogen 
agonist or antagonist”, “act as phytoestrogens”, “helps to keep healthy thermoregulation during 
climacterium”, and “helps to alleviate the symptoms of menopause”. The Panel assumes that the 
target population is post-menopausal women.  
In the context of the proposed wordings and the clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to the reduction of vasomotor symptoms associated with 
menopause. Changes in vasomotor symptoms associated with menopause such as frequency and 
severity of hot flushes and night sweats can be assessed using questionnaires. 
The Panel considers that reduction of vasomotor symptoms associated with menopause is a beneficial 
physiological effect. 
2.4. Maintenance of normal skin tonicity (ID 1704a) 
The claimed effect is “menopause/skin and hair health during menopause/cholesterol management”. 
The Panel assumes that the target population is post-menopausal women. 
In the context of the proposed wordings and the clarifications provided by Member States, the Panel 
assumes that the claimed effect refers to the maintenance of normal skin tonicity. No evidence has 
been provided on how skin tonicity could be related to skin function. 
The Panel considers that the claim does not refer to a function of the body as required by Regulation 
(EC) No 1924/2006. 
Soy isoflavones related health claims 
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2.5. Contribution to normal hair growth (ID 1704a, 4254) 
The claimed effect is “menopause/skin and hair health during menopause/cholesterol management” 
and “hair growth and loss”. The Panel assumes that the target population is the general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to normal 
hair growth. 
The Panel considers that contribution to normal hair growth is a beneficial physiological effect. 
2.6. “Cardiovascular health” (ID 3587) 
The claimed effect is “contributes to cardiovascular health”. The Panel assumes that the target 
population is the general population. 
The claimed effect is not sufficiently defined and no further details were provided in the proposed 
wordings. No clarifications were provided by Member States. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
2.7. Treatment of prostate cancer (ID 3588) 
The claimed effect is “contributes to maintain a healthy prostate and breast”. The Panel assumes that 
the target population is the general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to prostate 
function. Prostate function is not sufficiently defined. From the references provided, the Panel 
assumes that the claimed effect is related to the treatment of prostate cancer. 
The Panel considers that the claim is related to the treatment of disease and does not comply with the 
criteria laid down in Regulation (EC) No 1924/2006. 
2.8. “Upper respiratory tract” (ID 3589) 
The claimed effect is “contributes to the upper respiratory tract health”. The Panel assumes that the 
target population is the general population. 
The claimed effect is not sufficiently defined and no further details were provided in the proposed 
wordings. No clarifications were provided by Member States. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
3. Scientific substantiation of the claimed effect 
3.1. Protection of DNA, proteins and lipids from oxidative damage (ID 1286, 4245) 
Among the references provided were a number of narrative reviews and textbooks which were either 
not related to the claimed effect or did not provide any original data which could be used for the 
scientific substantiation of the claim. A number of human, animal and in vitro studies were not related 
to the claimed effect; these included references on endothelial function, antioxidant gene expression, 
metabolic syndrome, blood pressure, cholesterol concentrations, subarachnoid haemorrhage, 
Soy isoflavones related health claims 
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cardiovascular disease, atherosclerosis and symptoms associated with menopause. Some of the 
references provided did not address the food constituent which is the subject of the claim, but rather 
soy foods in general, or soy foods in combination with other foods. These studies did not control for 
other components besides isoflavones in these soy foods, which could have an effect on the protection 
of DNA, proteins and lipids from oxidative damage. The Panel considers that no conclusions can be 
drawn from these references for the scientific substantiation of the claim. 
Human intervention studies which assessed the effects of soy isoflavones on plasma total antioxidant 
status (DiSilvestro et al., 2006) and on ex vivo resistance of LDL to peroxidation (Jenkins et al., 2002; 
Nestel et al., 1997; Steinberg et al., 2003), and in vitro studies which assessed the effect of soy 
isoflavones on the oxidation lag time of LDL particles (Hwang et al., 2000) and on the resistance of 
HDL to copper-ion-induced peroxidation by measuring conjugated dienes (Ferretti et al., 2004) were 
provided. The Panel notes that the evidence provided does not establish that these markers predict 
peroxidation of LDL or HDL particles in vivo (Griffiths et al., 2002; Lapointe et al., 2006; Verhoye 
and Langlois, 2009). The Panel considers that no conclusions can be drawn from these references for 
the scientific substantiation of the claim.  
A randomised, double-blind, cross-over study by Wiseman et al. (2000) investigated the effects of 
diets low or high in soy isoflavones on lipid peroxidation in 24 healthy subjects aged 19-40 years. The 
subjects consumed textured soy protein as vegetarian burgers high (21.2 mg daidzein and 34.8 mg 
genistein) or low (0.9 mg daidzein and 1.0 mg genistein) in isoflavones for 17 consecutive days each, 
separated by a 25-day wash-out period. Two subjects did not complete the low-isoflavone 
intervention. Blood plasma concentrations of 8-epiprostaglandin F2α (8-epi-PGF2α), and 
malondialdehyde (MDA) measured by the HPLC-based thiobarbituric acid test, and resistance of LDL 
to copper-ion-induced peroxidation were assessed in 18 samples for each intervention period. The 
statistical analysis, which was corrected for multiple comparisons, was based on these samples only. 
The Panel notes the use of a valid biomarker to assess lipid peroxidation (8-epi-PGF2α determined by 
gas chromatography–mass spectrometry) and the inclusion of a marker which could be used as 
supportive (MDA measured by HPLC). The Panel notes that resistance of LDL to copper-ion-induced 
peroxidation is not a reliable marker to assess lipid peroxidation in vivo. The Panel also notes that 
25 % of the samples were not available for analysis, and that missing data were not taken into account 
in data analysis, and considers that no conclusions can be drawn from this study for the scientific 
substantiation of the claim.  
The Panel notes that no human studies from which conclusions could be drawn for the scientific 
substantiation of the claim were provided.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of soy isoflavones and protection of DNA, proteins and lipids from oxidative damage. 
3.2. Maintenance of normal blood LDL-cholesterol concentrations (ID 1135, 1704a, 3093a) 
Among the references provided were a number of narrative reviews and textbooks which were either 
not related to the claimed effect or did not provide any original data which could be used for the 
scientific substantiation of the claim. A number of human, animal and in vitro studies did not address 
changes in LDL-cholesterol concentrations; these included references on the effect of soy isoflavones 
on symptoms associated with menopause, severity of asthma, DNA damage, mood, cognitive 
function, bone loss, bone fractures, cancer, LDL peroxidation, weight loss, inflammation, 
cardiovascular disease risk, deposition of cholesterol in the aorta and endothelial function. Some of 
the references provided did not address the food constituent, which is the subject of the claim, but 
addressed soy isoflavones in combination with other substances, or red clover isoflavones.  
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Fifty-five human intervention studies were provided either separately in the consolidated list or in the 
four meta-analyses which assessed the effect of soy isoflavones as extracts, pure compounds or in soy 
protein on blood cholesterol concentrations. 
Some human intervention studies used soy nuts (Welty et al., 2007b), soy foods in general (Chiechi et 
al., 2002; Scheiber et al., 2001), soy meal replacement formula (Allison et al., 2003), soy protein 
containing isoflavones (Maesta et al., 2007; Sagara et al., 2004; Washburn et al., 1999) or a soy 
extract, fibre and lecithin supplement (Puska et al., 2002), without controlling either for the protein 
component, the amount of lecithin contained or the macronutrient composition, which could have an 
effect on blood cholesterol concentrations. In one study (Takatsuka et al., 2000), the nature of the 
control diet was not specified. Two studies, one of which was uncontrolled, did not report the amount 
of isoflavones administered (Wong et al., 1998; Yildirir et al., 2001). One study examined the effect 
of soy isoflavones on post-prandial cholesterol concentrations only (Campbell et al., 2006), one study 
assessed total cholesterol concentrations without reporting on LDL-cholesterol or other cholesterol 
fractions (Urban et al., 2001), and one study purported to have evaluated blood cholesterol 
concentrations but did not report any results (Scambia et al., 2000). In four studies (Basaria et al., 
2009; Jenkins et al., 2000; Jenkins et al., 2002; West et al., 2005) some subjects took medication such 
as hormone replacement therapy (HRT), levothyroxine or cholesterol lowering medication which 
could have an impact on the claimed effect, and it was unclear whether the sub-group analysis 
performed in subjects not taking medication in one of these studies (West et al., 2005) was 
pre-planned or not. In one study, subjects who dropped out were replaced after randomisation 
(Lichtenstein et al., 2002), introducing possible selection bias. In a further study, subjects in the 
intervention and placebo groups were significantly different with respect to their total and 
LDL-cholesterol concentrations at baseline, and it was unclear how this difference was taken into 
account in the analysis (Petri Nahas et al., 2004). Three cross-sectional studies (de Kleijn et al., 2002; 
Nagata et al., 1998; Somekawa et al., 2001) were provided which investigated the association between 
soy consumption and changes in blood LDL-cholesterol concentrations. The Panel notes that the 
observational study design does not allow controlling with sufficient precision for the macronutrient 
composition of the diets and medication use, both of which could have an effect on blood cholesterol 
concentrations, besides isoflavones. The Panel considers that no conclusions can be drawn from these 
references for the scientific substantiation of the claim. 
A meta-analysis of randomised controlled trials (RCTs) (Taku et al., 2008), which assessed the effects 
of consumption of extracted soy isoflavones vs. placebo on blood LDL-cholesterol concentrations, 
included the individual studies of this type which were provided in the consolidated list (Cheng et al., 
2007; Gonzalez et al., 2007) except three (Atteritano et al., 2007; Lissin et al., 2004; Nahas et al., 
2007).  
In the meta-analysis by Taku et al. (2008), several databases were searched for RCTs published 
between 1966 and 2007. Reference lists of relevant systematic reviews and meta-analyses were hand 
searched. Twelve studies met the inclusion criteria of RCTs conducted in adults and published in 
English, Japanese or Chinese, with duration of 1-3 months. Six trials used a parallel design and the 
remaining trials used a cross-over design. The study population was post-menopausal women (n=565) 
in all studies, and doses of total isoflavones were 27-132 mg/day expressed as aglycone equivalents. 
In most of the studies included, women consumed similar diets with similar amounts of fat, 
cholesterol and fibre, and no significant body weight changes were reported during the study period. 
The funnel plots did not indicate publication bias. Using either a random or a fixed (i.e. when studies 
responsible for significant heterogeneity were removed from analysis) effects model, no effect of 
isolated soy isoflavone consumption on total (ten studies) or LDL-cholesterol (nine studies) 
concentrations was observed. The Panel notes that no justification has been provided for excluding 
studies with a duration longer than three months, and that this meta-analysis does not show an effect 
of extracted soy isoflavones on blood cholesterol concentrations when consumed for 1-3 months at 
doses of 27-132 mg/day. 
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In a randomised double-blind, placebo-controlled parallel study conducted in 389 post-menopausal 
women (49-67 years), the effect of genistein administration (54 mg/day) for 24 months on total and 
LDL-cholesterol concentrations was investigated (Atteritano et al., 2007). After a run-in phase of four 
weeks in which all women followed a fat-restricted diet, women were assigned to consume either 
genistein (n=198) or placebo (n=191) in the form of capsules. All capsules also contained 500 mg 
calcium and 400 IU vitamin D. Eighty-five subjects withdrew before completion of the study (48 in 
the genistein group and 37 in the placebo group). Analyses were performed in the intention-to-treat 
population. No significant changes in total or LDL-cholesterol concentrations were observed between 
groups at either 12 or 24 months. The Panel notes that this study does not show an effect of genistein 
consumption on blood cholesterol concentrations. 
In a randomised, double-blind, placebo-controlled parallel study 80 post-menopausal women (mean 
age approx. 55 years) were allocated to consume daily either 100 mg of isoflavones in 250 mg 
standardised soy extract (n=40) or placebo (lactose; n=40) for ten months (Nahas et al., 2007). Four 
subjects dropped out during the study (two in the intervention group (n=38 analysed) and two in the 
placebo group (n=38 analysed)) and were not taken into account in the analysis. No statistically 
significant differences were observed between the isoflavone and the placebo group with respect to 
total or LDL-cholesterol concentrations. The Panel notes that missing data have not been taken into 
account in the analysis, and that this study does not show an effect of extracted soy isoflavones on 
blood cholesterol concentrations. 
In another randomised, double-blind, placebo-controlled parallel trial, 40 post-menopausal women 
(mean age 61.6±8.4 years) with moderate hypercholesterolaemia were assigned to consume for six 
weeks either 2x45 mg/day soy isoflavones in tablet form (n=20) or placebo (n=20), which was 
identical in composition but isoflavone-free (Lissin et al., 2004). All women completed the study. No 
significant changes in total or LDL-cholesterol concentrations were observed between groups. The 
Panel notes that this study does not show an effect of extracted soy isoflavones on blood cholesterol 
concentrations.  
The Panel notes that one meta-analysis including nine RCTs, and three additional RCTs, did not show 
an effect of extracted soy isoflavones on blood LDL-cholesterol concentrations.  
Three meta-analyses and 23 human intervention studies were provided which assessed the effect of 
soy isoflavones in soy protein against isoflavone-depleted soy protein or animal protein. 
The meta-analyses by Zhuo et al. (2004) and Taku et al. (2007) investigated the effects of 
consumption of soy isoflavones in isolated soy protein (ISP
+
) compared to isoflavone-depleted ISP 
(ISP
-
) on blood cholesterol concentrations in meta-analyses of RCTs published between 1966 and 
2003, and between 1990 and 2006, respectively, with duration of 1-3 months, using either a parallel or 
cross-over design and which provided baseline and endpoint blood cholesterol concentrations. Eight 
(n=471 subjects) and eleven (n=441 subjects) studies, respectively, met the inclusion criteria. The 
Panel notes that with the exclusion of studies comparing ISP
+
 to animal protein these meta-analyses 
did not include all the studies pertinent to the claim, and considers that no conclusions can be drawn 
from these meta-analyses for the scientific substantiation of the claim. 
Zhan and Ho (2005) conducted a meta-analysis of RCTs published in English between 1995 and June 
2002 on the effect of ISP
+
 or isoflavone extracts on blood lipid concentrations. Twenty-three studies 
(n=1,381 subjects) met the inclusion criteria (RCTs providing the amount of soy isoflavones and 
blood lipid concentrations at baseline). The study duration ranged from 3 to 26 weeks. Seventeen 
studies used ISP
+
, three used tablets containing extracted isoflavones, and three used textured soy 
foods. In sub-group analyses, eight comparisons (n=440) were made for ISP
+
 vs. ISP
-
, 27 comparisons 
(n=1,501) for ISP
+
 vs. casein, and three comparisons (n=135) for extracted soy isoflavones vs. 
placebo. The Panel notes that in two studies (Puska et al., 2002; Washburn et al., 1999) the control 
was not appropriate to assess the effects of soy isoflavones in soy protein (i.e. carbohydrates and no 
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isoflavone-free control, and the intervention and control not matched with respect to the lecithin 
content). One study included subjects on HRT, levothyroxin and lovastatin (Jenkins et al., 2000), and 
one study assessed the effects of red clover isoflavones rather than soy isoflavones (Hodgson et al., 
1998). It is also unclear which studies were included in the sub-group analyses with respect to ISP
+
 vs. 
ISP
-
, and with respect to ISP
+
 vs. casein, or the reasons for excluding from the sub-group analyses 
those studies which used animal proteins other than casein (e.g. whey and total milk protein) as 
control. The Panel notes the methodological limitations of this meta-analysis and considers that no 
conclusions can be drawn from this meta-analysis for the scientific substantiation of the claim. 
All of the individual studies described below were either provided in the three meta-analyses 
described above or provided separately in the consolidated list. 
In a double-blind, randomised, controlled parallel trial, 202 healthy post-menopausal women (60 to 
75 years) with mean baseline LDL-cholesterol concentrations of 4.1 mmol/L were assigned to receive 
daily 25.6 g soy protein containing 99 mg isoflavones (n=100) or total milk protein (n=102) as a 
powder for 12 months (Kreijkamp-Kaspers et al., 2004). Power calculations were made for three 
outcome variables, including total cholesterol. It was estimated that 100 subjects per group had to be 
recruited to detect a 7.4 % difference in total cholesterol concentrations between groups with a power 
of 80 %, α=0.05, and a drop-out rate of 25 %. A total of 49 subjects withdrew from the study (24 in 
the placebo group, 25 in the soy group). A modified intention-to-treat analysis was used including all 
subjects with at least two measurements, including baseline plus a close-out visit (n=22, 9 in the 
placebo group (n=87 analysed), 13 in the soy group (n=88 analysed)). No statistically significant 
differences were found in total or LDL-cholesterol concentrations between the soy and the placebo 
group. The Panel notes that this adequately powered study does not show an effect of soy isoflavones 
in soy protein on blood cholesterol concentrations. 
In a double-blind, randomised, controlled parallel intervention 213 healthy subjects (105 women, 
50-75 years) with mean baseline blood LDL-cholesterol concentrations of approx. 3.85 mmol/L were 
assigned to consume daily either 40 g of soy protein powder with 188 mg of soy isoflavones (n=105) 
or casein powder (n=108) to be mixed with beverages for three months (Teede et al., 2001). 
Thirty-four subjects (19 in the soy group and 15 in the placebo group did not complete the study and 
were not taken into account in the analysis (n=86 analysed on the soy group and n=93 analysed in the 
placebo group). No statistically significant differences were observed between groups with respect to 
total or LDL-cholesterol concentrations. The Panel notes that missing data were not taken into 
account in the analysis, and that this study does not show an effect of soy isoflavones in soy protein 
on blood cholesterol concentrations. 
The randomised, double-blind, controlled parallel study by Allen et al. (2007) was designed to assess 
the effects of soy isoflavones in soy protein on LDL-cholesterol concentrations. A total of 216 
post-menopausal women (mean age: approx. 57 years) with mean baseline LDL-cholesterol 
concentrations of approx. 3.6 mmol/L were assigned to consume 20 g/day soy protein containing 
160 mg total isoflavones (96 mg aglycones; n=107) or 20 g/day whole milk protein (control; n=109) 
for 12 weeks after a one-month, single-blind, run-in period to select women with high (>80 %) 
compliance with the study products. A total of 25 women (14 in the soy and 11 in the control group) 
dropped out during the study and their baseline measures were used for missing data. The authors 
reported a statistically significant decrease in total and LDL-cholesterol concentrations after 
controlling for associated variables (age, race, weight change, change in dietary fat intake, energy 
expenditure) in the soy compared to the placebo group at week 6 but not at week 12. The Panel notes 
that carrying forward observations is not an appropriate method of taking into account missing data 
and that this study does not show a sustained effect of soy isoflavones in soy protein on blood 
cholesterol concentrations.  
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A randomised, double-blind, controlled parallel trial which included 182 hyperlipidaemic men and 
women (44 % male, 30-70 years, mean baseline cholesterol concentrations not reported), assessed the 
effects on blood cholesterol concentrations of the consumption of a supplement containing 31.5 g/day 
soy protein and 120 mg/day isoflavones (as aglycones) (n=81 analysed) compared to a milk protein 
supplement (28.5 g/day; n=78 analysed) for five weeks after a three-week run-in period on the milk 
protein supplement (Ma et al., 2005). Twenty-two subjects dropped out (six before randomisation and 
eight in each group during the study), and a further subject was not included in the analysis, which 
was performed in completers only. No statistically significant differences were found between the two 
groups with respect to changes in total or LDL-cholesterol concentrations. The Panel notes that 
missing data were taken into account in the analysis, and that this study does not show an effect of soy 
isoflavones in soy protein on blood cholesterol concentrations. 
In a double-blind, randomised cross-over study 43 male subjects (mean age: approx. 28 years) with 
mean baseline blood LDL-cholesterol concentrations of 2.74±1.06 mmol/L consumed daily either ISP 
containing 0.75 mg/kg body weight of isoflavones (around 32 g ISP with 62 mg isoflavones per day) 
(ISP
+
), ISP containing low amounts of isoflavones (around 1.6 mg per day) (ISP
-
) and milk protein 
powder for periods of 57 days each with a 28-day wash-out period in between (McVeigh et al., 2006). 
Four subjects dropped out during the study and a further four were excluded from analysis 
(35 subjects analysed). No statistically significant differences were observed between any of the 
periods with respect to total or LDL-cholesterol concentrations. The Panel notes that missing data 
were not taken into account in the analysis, and that this study does not show an effect of soy 
isoflavones in soy protein on blood cholesterol concentrations. 
The double-blind, randomised, controlled parallel intervention by Vigna et al (2000) assessed the 
effects on cholesterol concentrations of daily consumption of 60 g ISP containing 76 mg isoflavones 
(n=51) compared to casein (n=53) in 104 post-menopausal women (mean age: approx. 53 years) with 
mean baseline LDL-cholesterol concentrations of approx. 4.2 mmol/L. Eleven subjects from the ISP 
group and 14 subjects from the placebo group dropped out during the study, and a further two subjects 
from the placebo group were excluded from analysis (n=40 analysed in the ISP group and n=37 
analysed in the placebo group). No statistically significant differences were found between the two 
groups with respect to changes in total or LDL-cholesterol concentrations. The Panel notes that 
missing data were not taken into account in the analysis, and that this study does not show an effect of 
soy isoflavones in soy protein on blood cholesterol concentrations. 
In a double-blind, randomised cross-over study, 42 post-menopausal women (mean age: approx. 
55 years) with mean baseline blood LDL-cholesterol concentrations of 2.89±0.1 mmol/L consumed 
ISP with 107.67 mg of total isoflavones (aglycone units), ethanol-washed ISP with 1.82 mg total 
isoflavones, and total milk protein, in a daily dose of 25 g protein for periods of six weeks each with a 
four-week wash-out period in between (Steinberg et al., 2003). A total of 14 women withdrew from 
the study and were not taken into account in the analysis (28 subjects analysed). There were no 
statistically significant changes in total or LDL-cholesterol concentrations between any of the periods. 
The Panel notes that missing data were not taken into account in the analysis, and that this study does 
not show an effect of soy isoflavones in soy protein on blood cholesterol concentrations. 
In a double-blind, randomised, controlled parallel intervention, 69 women (42-62 years) (baseline 
total or LDL-cholesterol concentrations not reported) received either ISP containing 80.4 mg/day 
isoflavone aglycone components (ISP
+
, n=24), 4.4 mg/day isoflavone aglycone components (ISP
-
, 
n=24) or control (whey protein, n=20) in the form of muffins and soy or placebo powder as meal 
replacements for 24 weeks in four different cohorts in which the interventions were equally 
represented (Dent et al., 2001). One control subject was not included in the analyses. No statistically 
significant effect of soy isoflavones on total or LDL-cholesterol concentrations between groups was 
found at any time point (12 and 24 weeks). The Panel notes that this study does not show an effect of 
soy isoflavones in soy protein on blood cholesterol concentrations. 
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The paper by Mackey et al. (2000) reported on two human intervention studies, one of which was a 
sequential study without wash-out period in between and for which it was unclear whether the control 
diet was matched to the intervention diet with respect to macronutrient composition, which could 
have an impact on the claimed effect. The Panel considers that no conclusions can be drawn from this 
study for the scientific substantiation of the claim. The other study reported in the paper was a 
double-blind, randomised, controlled parallel intervention in 54 post-menopausal women (mean age: 
approx. 56 years) with total cholesterol concentrations >5.5 mmol/L and mean baseline 
LDL-cholesterol concentrations of 5.1 mmol/L, who consumed daily 28 mg of soy protein powder 
containing 65 mg isoflavones (ISP
+
, n=22 analysed) or <4 mg isoflavones (ISP
-
, n=24 analysed) after 
a four-week run-in period in which the dietary guidelines from the National Heart Foundation were 
followed. Eight subjects did not complete the study (group not reported) and were not taken into 
account in the analysis. No statistically significant differences were observed between groups with 
respect to total or LDL-cholesterol concentrations. The Panel notes that missing data were not taken 
into account in the analysis, and that this study does not show an effect of soy isoflavones in soy 
protein on blood cholesterol concentrations.  
In a randomised, single-blind, controlled parallel trial, 43 obese women (20-65 years) with mean 
baseline LDL-cholesterol concentrations of approx. 3.0 mmol/L were assigned to consume daily, in 
the context of an energy-restricted diet, either three soy-based isoflavone-containing (91 g protein, 
150 mg isoflavones (aglycones); n=22) or three casein-based (n=21) meal replacement shakes for 
16 weeks after a two-week run-in period (Anderson et al., 2007). The shakes were matched with 
respect to their macronutrient composition, but differed in their calcium, potassium and isoflavone 
content. Eight women did not complete the study (three in the casein and five in the soy group) and 
were not taken into account in the analysis (n=17 analysed in the soy group and n=18 analysed in the 
placebo group). No statistically significant differences were observed between the soy and the casein 
group with respect to total or LDL-cholesterol concentrations. The Panel notes that missing data were 
not taken into account in the analysis, and that this study does not show an effect of soy isoflavones in 
soy protein on blood cholesterol concentrations. 
In a double-blind, randomised cross-over trial Merz-Demlow et al. (2000) studied the effects of 
consuming 75-100 g of soy powder (depending on the subject‟s body weight), which provided an 
average of 53 g protein and 10 mg (control), 65 mg (low isoflavone) and 129 mg (high isoflavone) soy 
isoflavones (aglycone units), on cholesterol concentrations in the different phases of the menstrual 
cycle in 20 women (mean age: 26.3±4.8 years). The intervention covered three menstrual cycles plus 
nine days, with wash-out periods of 2-3 weeks in between during which an ad libitum diet was 
consumed. Six subjects did not complete the intervention and a further subject was excluded from 
analysis (13 subjects analysed). Compared with the control diet the high isoflavone diet lowered 
LDL-cholesterol concentrations significantly, by 7.6 % and 10 %, in the midfollicular and 
periovulatory phases, respectively, (p<0.02) but not in the early follicular and midluteal phases. The 
Panel notes that this study evaluated cholesterol lowering effects during menstrual phases only, and 
did not show a sustained effect of soy isoflavones in soy protein on blood cholesterol concentrations. 
In a double-blind, randomised, controlled parallel trial, 57 post-menopausal women (47-72 years) with 
mean baseline LDL-cholesterol concentrations of approx. 3.7 mmol/L were allocated to consume 40 g 
ISP containing either 1.2 mg isoflavones and 0.22 g phytate (LP/LI, n=14 analysed), 1.2 mg 
isofavones and 0.64 g phytate (NP/LI, n=13 analysed), 85.8 mg isoflavones and 0.22 g phytate 
(LP/NI, n=14 analysed), or 84.6 mg isoflavones and 0.78 g phytate (NP/NI, n=14 analysed) in the 
form of smoothies or other foodstuffs for six weeks (Engelman et al., 2005). Two subjects did not 
complete the study (group not reported) and were not taken into account in the analysis. No 
statistically significant differences were observed between groups with respect to total or 
LDL-cholesterol concentrations. The Panel notes that this study does not show an effect of soy 
isoflavones in soy protein on blood cholesterol concentrations.  
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In a 15-month, double-blind, randomised, controlled parallel intervention, which involved nine 
months of dietary intervention and a six-month (intervention-free) follow-up, 65 post-menopausal 
women (mean age: approx. 55 years) with mean baseline cholesterol concentrations of approx. 
3.5 mmol/L were assigned to consume daily either 40 g ISP with 96 mg isoflavones (n=17 analysed), 
40 g ISP with 52 mg isoflavones (n=19 analysed) or ISP containing 4 mg isoflavones (n=14 analysed) 
(Gallagher et al., 2004). Fifteen women (group not reported) dropped out during the study and were 
not taken into account in the analysis. No statistically significant differences were observed between 
groups with respect to total or LDL-cholesterol concentrations at the end of the intervention. The 
Panel notes that missing data were not taken into account in the analysis, and that this study does not 
show an effect of soy isoflavones in soy protein on blood cholesterol concentrations. 
In a double-blind, randomised cross-over trial, Meinertz et al. (2002) studied the effect of consuming 
total liquid diets composed of casein, soy protein or ethanol-extracted soy protein in 12 subjects 
(6 women; 22-68 years) with mean baseline LDL-cholesterol concentrations of 2.1±0.5 mmol/L for 
32 days each, with wash-out periods of at least 18 days in between in which self-selected solid foods 
were consumed. The Panel assumes that the diets provided 140 g of ISP with 335 mg isoflavones, 
140 g of ISP with 15.4 mg of isoflavones and 139 g of casein. No information on drop-outs was 
provided. No statistically significant differences were observed between the three diets with respect to 
total or LDL-cholesterol concentrations. The Panel notes that this study does not show an effect of 
soy isoflavones in soy protein on blood cholesterol concentrations. 
The double-blind, controlled parallel intervention by Gardner et al. (2001) assessed the effect of daily 
consumption during 12 weeks of 42 mg ISP containing 80 mg of isoflavones (ISP 80; n=31 analysed) 
or trace amounts of isoflavones (ISP
-
, n=33 analysed), or milk protein (n=30 analysed) to be mixed 
with beverages in 115 post-menopausal women (mean age: approx. 60 years) with mean baseline 
LDL-cholesterol concentrations of approx. 4.2 mmol/L. During the four-week run-in phase in which 
the milk protein supplement was consumed, and before randomisation, 15 women dropped out, and a 
further six (three in the ISP 80, one in the ISP
-
 and two in the milk protein group) did not complete the 
study after randomisation and were not taken into account in the analysis. It was estimated that 
30 subjects per group would provide 80 % power to detect a difference in change in LDL-cholesterol 
concentrations of 10 %, using an α=0.05. A statistically significant difference between the ISP 80 and 
the ISP
-
 group was observed with respect to total and LDL-cholesterol concentrations at the end of the 
study (-0.27 vs. -0.02 mmol/L, p=0.03 and -0.38 vs. -0.09 mmol/L, p=0.005, respectively). No 
significant differences were observed between any of the ISP groups compared to the milk protein 
group. The Panel notes that missing data were not taken into account in the analysis and that this 
study shows an effect on blood cholesterol concentrations of ISP
+
 when compared to ISP
-
, but not if 
ISP
+
 was compared to animal protein. The Panel also notes that the results of this study are 
inconsistent with respect to the effects of soy isoflavones in soy protein on blood cholesterol 
concentrations. 
In a randomised, cross-over study (Ashton and Ball, 2000), 45 healthy males (34-62 years) with mean 
baseline LDL-cholesterol concentrations of 3.68±0.86 mmol/L consumed a tofu-based diet 
(290 g tofu/day) providing 80 mg isoflavones per day, and a meat-based diet (150 g cooked lean red 
meat), for four weeks each with a two-week wash-out period in between. All subjects consumed 
similar vegetarian breakfasts, lunches and snacks on both diets, and diets were comparable with 
respect to macronutrient composition (except for the amount of cholesterol they provided). Three 
subjects did not complete the study and were not taken into account in the analysis (42 subjects 
analysed). Compared to the meat diet, total cholesterol concentrations were significantly lower in the 
tofu diet period (mean difference: 0.23, 95 % CI 0.02, 0.43), whereas no statistically significant 
differences were observed for LDL-cholesterol concentrations. The Panel notes that missing data 
were not taken into account in the analysis, and that this study shows an effect of soy isoflavones in 
soy foods on total blood cholesterol concentrations. 
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In a randomised, blinded, controlled parallel intervention, 82 post-menopausal women (aged 
45-55 years) with mean baseline LDL-cholesterol concentrations of 3.4 mmol/L were assigned to 
consume daily either 150 mg soy protein and 100 mg isoflavones in capsules (n=41) or placebo 
capsules containing the same amount of isoflavone-free soy protein plus glucose (n=41) for four 
months (Han et al., 2002). One subject from each group dropped out during the study. Total and 
LDL-cholesterol concentrations significantly decreased in the isoflavone group compared to placebo 
(mean change: -26.6±1.2 mg/dL vs. 0.2±0.4 mg/dL, and -13.3±1 mg/dL vs. 5.5±1.2 mg/dL, for total 
and LDL–cholesterol concentrations, respectively, p<0.001). The Panel notes that only basic 
statistical analyses were performed, and that this study shows an effect of soy isoflavones in soy 
protein on blood cholesterol concentrations. 
In a double-blind, placebo controlled, parallel trial, 159 subjects (25 women; mean age: 52 years) with 
LDL-cholesterol concentrations ≥4 mmol/L, after having followed an American Heart Association 
Step I diet for 4-24 weeks and having mean baseline LDL-cholesterol concentrations of approx. 
4.8 mmol/L, were randomised to one of four groups to consume in the form of beverages, while 
continuing the Step I diet: 30 g ISP with 111 mg isoflavones and 10 g cotyledon fibre (n=39): 50 g 
ISP with 185 mg isoflavones and 16.6 g cotyledon fibre (n=40): 30 g casein and 10 g cellulose (n=40) 
or 50 g casein and 16.6 g cellulose (n=40) for 16 weeks (Tonstad et al., 2002). The study was 
designed to have 90 % power to detect a 10 % relative change in total cholesterol concentrations 
(assuming an SD of 10 %) between groups for pair-wise comparisons with a two-sided p<0.05. 
Nineteen subjects did not complete the study and a further 10 were not included in the per protocol 
analysis (five in the 30 g ISP group (n=34 analysed), four in the 30 g casein group (n=36 analysed), 
nine in the 50 g ISP group (n=31 analysed) and 11 in the 50 g casein group (n=29 analysed)). In 
addition, all subjects who received the intervention for four weeks or longer were included in a 
modified intention-to-treat analysis. In the per-protocol analysis there was a statistically significant 
difference in the decrease in total and LDL-cholesterol concentrations between the two ISP and the 
two casein groups, as pooled together (difference in change: -0.24, 95 % CI -0.43, -0.04 and -0.26, 95 
% CI -0.43, -0.09, p=0.01 for the interaction between time and treatment). The modified intention-to-
treat analysis yielded similar results. The interaction between time and dose was not significant. The 
Panel notes that separate analyses for the different groups as compared to the respective controls were 
not reported. The Panel notes that this study shows an effect of soy isoflavones in soy protein on 
blood cholesterol concentrations. 
In a double-blind, randomised, controlled parallel intervention, 156 subjects (62 females; 
20-70 years), with baseline LDL-cholesterol concentrations between 3.6 and 5.2 mmol/L after a 
one-month run-in period on a National Cholesterol Education Program (NCEP) Step I diet, and a 
further month on casein beverages (in addition to the NCEP Step I diet), were allocated to consume 
daily one of the following: 25 g of soy protein with either 3 mg isoflavones (ISP 3; n=28 analysed), 
27 mg isoflavones (ISP 27; n=27 analysed), 37 mg isoflavones (ISP 37; n=30 analysed) and 62 mg 
isoflavones (ISP 62; n=30 analysed) or 25 g casein (n=31 analysed) for nine weeks (Crouse et al., 
1999). The study was designed to enrol 30 participants per group to evaluate 25 (assuming drop-outs) 
and have 95 % power to detect a 6 % relative change in LDL-cholesterol concentrations between 
groups for pair-wise group comparisons at the 5 % two-sided level of significance. Twelve subjects 
(three in the casein, four in the ISP 3 and five in the ISP 27 group) did not complete the study. Plasma 
lipids were measured at weeks 8 and 9, and an average of these two measurements was taken for 
analysis. The analysis was reported to have been performed on an intention-to-treat basis, although 
from the information provided it appeared that data from ten subjects were not taken into account in 
the analysis. Only the ISP 62 group significantly reduced total cholesterol concentrations, i.e. by 4 % 
(-0.25 mmol/L; 95 % CI -0.49, -0.0003), and LDL-cholesterol concentrations, i.e. by 6 % 
(-0.27 mmol/L; 95 % CI -0.47, -0.06) as compared to casein. There was a statistically significant 
dose-response relationship between the intake of isoflavones and a decrease in total and 
LDL-cholesterol concentrations (p=0.01 and p=0.02 for the trends for total and for LDL-cholesterol 
concentrations, respectively). No effect on either total or LDL-cholesterol concentrations was 
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observed for ISP 3 or ISP 27. The Panel notes that this study shows an effect of soy isoflavones in soy 
protein on blood cholesterol concentrations. 
In a double-blind, randomised controlled parallel trial, 81 post-menopausal women (mean age: 
approx. 60 years) with baseline plasma cholesterol concentrations between 6.2 and 7.8 mmol/L and 
mean baseline blood non-HDL-cholesterol concentrations of approx. 1.4 mmol/L, after having 
followed a 2-week run-in period on an NCEP Step I diet, were studied during three separate 24-week 
cohorts in which subjects were assigned to consume daily, in the context of an NCEP Step I diet, 40 g 
ISP containing 56 mg aglycone isoflavones (ISP 56; n=23 analysed), 40 g ISP containing 90 mg 
aglycone isoflavones (ISP 90; n=21 analysed) or 40 g casein and non-fat dry milk in the form of baked 
goods or ready-to-mix beverages and soups (Baum et al., 1998). Seven subjects dropped out during 
the intervention, and a further eight were not taken into account in the analysis (group not reported). 
No statistically significant differences were observed with respect to total cholesterol concentrations 
for either of the two ISP groups compared to placebo at any time point. Non-HDL cholesterol 
concentrations were significantly different between the ISP 56, the ISP 90 and the control groups 
(adjusted (for baseline means) mean difference: -0.28 and -0.25 mmol/L; p=0.03 and p=0.04, 
respectively) at the end of the study. The Panel notes that missing data were not taken into account in 
the analysis, and that this study shows an effect of soy isoflavones in soy protein on blood non-HDL 
cholesterol concentrations. 
In a double-blind, randomised cross-over study, 23 post-menopausal women (mean age: 
approx. 57 years) with mean baseline blood LDL-cholesterol concentrations of approx. 3.5 mmol/L 
consumed daily 63 g ISP with 7.1±1.1 mg isoflavones (control diet), 65±11 mg isoflavones 
(low isoflavone diet), and 13±22 mg isoflavones (high isoflavone diet) for periods of 93 days each 
with a 26-day wash-out period in between (Wangen et al., 2001). Four subjects dropped out during the 
first diet period, and a further one was excluded from the analysis (18 subjects were analysed for the 
control and high isoflavone diet and 17 for the low isoflavone diet). Repeated measures analysis of 
variance showed a statistically significant difference between the three diets with respect to 
LDL-cholesterol concentrations (p=0.01), but not with respect to total cholesterol concentrations. The 
Panel notes that missing data were not taken into account in the analysis, and that this study shows an 
effect of soy isoflavones in soy protein on blood LDL-cholesterol concentrations. 
In a double-blind, randomised cross-over trial, Hermansen et al. (2001) studied the effect on blood 
cholesterol concentrations of consuming 50 g ISP with >165 mg soy isoflavones and 20 g soy 
cotyledon fibre as compared to 50 g casein and 20 g cellulose for six weeks with a three-week 
wash-out period in between in 25 type 2 diabetic subjects of whom 20 completed the intervention 
(6 women, mean age approx. 64 years, mean baseline LDL-cholesterol concentrations: approx. 
3.6 mmol/L). Analysis was performed in the population of completers. The percentage mean 
treatment difference between the two periods was statistically significant for LDL-cholesterol 
concentrations (10±15 %, p<0.05), but not for total cholesterol concentrations. The Panel notes that 
missing data were not taken into account in the analysis, and that this study shows an effect of soy 
isoflavones in soy protein on blood LDL-cholesterol concentrations. 
In a double-blind, randomised, controlled parallel intervention, 92 men (23-74 years) with baseline 
total cholesterol concentrations between 5.69 and 7.76 mmol/L were allocated, after a three-week 
run-in period on an NCEP Step I diet, to consume daily either 50 g ISP with 95 mg isoflavones 
(n=15 analysed), 40 g ISP, 10 g casein and 76 mg isoflavones (n=17 analysed), 30 g ISP, 20 g casein 
and 57 mg isoflavones (n=18 analysed), 20 g ISP, 30 g casein and 38 mg isoflavones (n=15 analysed) 
or 50 g casein (n=16 analysed) in the form of baked goods or ready-to-mix beverages for six weeks in 
three separate cohorts (Teixeira et al., 2000). Eight subjects dropped out during the study, and a 
further three were not taken into account in the analysis (groups not reported). Non-HDL cholesterol 
concentrations were significantly different in all ISP groups compared to control at six weeks 
(adjusted (for baseline) mean change: -0.182 (50 g ISP), -0.095 (40 g ISP), -0.163 (30 g ISP), 
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-0.139 (20 g ISP) vs. +0.224 (control) mmol/L, p<0.05). Total cholesterol changes were significant for 
the 50 g, 30 g and 20 g ISP groups (but not for the 40 g ISP group) as compared to control at six 
weeks (adjusted mean change: -0.167 (50 g ISP), -0.115 (30 g ISP), -0.126 (20 g ISP) vs. 
0.222 (control) mmol/L, p<0.05). The Panel notes that missing data were not taken into account in the 
analysis and that this study shows an effect of soy isoflavones in soy protein on blood cholesterol 
concentrations. 
The Panel notes that out of the 23 human intervention studies in which soy isoflavones were 
consumed in soy protein from which conclusions could be drawn for the scientific substantiation of 
the claim, 14 studies (n=1,286 subjects, 12-93 subjects per group/period) with durations between one 
and 12 months using isoflavone doses of around 60-330 mg per day did not show an effect of soy 
isoflavones on blood cholesterol concentrations in subjects with slightly elevated or high blood 
LDL-cholesterol concentrations, whereas eight studies (n=712 subjects, 15-42 subjects per 
group/period) with durations between six weeks and six months using isoflavone doses of around 
30-185 mg per day showed a statistically significant effect in subjects with normal to high blood 
LDL-cholesterol concentrations, and one study (n=94 subjects, around 30 per group) led to 
inconsistent results with respect to the effect of soy isoflavones on blood LDL-cholesterol 
concentrations. The Panel also notes that most of the studies had some methodological limitations, 
and that the inconsistent results reported appear unrelated to the dose of isoflavones used, the study 
duration, the sample size or the baseline characteristics of subjects with respect to blood cholesterol 
concentrations.  
In weighing the evidence, the Panel took into account that one meta-analysis of nine RCTs and three 
additional RCTs did not show an effect of extracted soy isoflavones on blood cholesterol 
concentrations and that the evidence provided by 23 RCTs in which soy isoflavones were consumed 
in soy protein is inconsistent.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of soy isoflavones and maintenance of normal blood LDL-cholesterol concentrations. 
3.3. Reduction of vasomotor symptoms associated with menopause (ID 1654, 1704b, 2140, 
3093b, 3154, 3590) 
Among the references provided for the scientific substantiation of the claim were narrative reviews 
which were either unrelated to the claimed effect or did not contain any original data which could be 
used for the scientific substantiation of the claim. A number of human, animal and in vitro studies 
were unrelated to the claimed effect. These references included studies on the effect of soy 
isoflavones on blood lipid concentrations, severity of asthma, DNA damage, mood, cognitive 
function, bone loss, bone fractures, cancer incidence, LDL peroxidation, weight loss, inflammation, 
cardiovascular disease risk and endothelial function. Some human intervention studies used food 
constituents other than soy isoflavones (e.g. red clover isoflavones) or a combination of soy 
isoflavones with other constituents (Brzezinski et al., 1997; Campagnoli et al., 2005). Three 
publications were available only in the form of a brief communication (Jou et al., 2005; Ricciotti et 
al., 2005) or an abstract (Imhof et al., 2008) which did not provide sufficient information with regard 
to the study design and the statistical analysis for a full scientific evaluation. One prospective cohort 
study (Nagata et al., 2001) and two cross-sectional studies (Nagata et al., 1999; Somekawa et al., 
2001) which investigated the association of consumption of soy isoflavones and soy products with 
vasomotor symptoms associated with menopause were provided. The Panel notes that these studies 
were not sufficiently controlled for other dietary factors or medication use both of which could have 
an effect on vasomotor symptoms. The Panel considers that no conclusions can be drawn from these 
references for the scientific substantiation of the claim.  
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Two meta-analyses (Howes et al., 2006; Nelson et al., 2006), six systematic reviews (Howes et al., 
2006; Huntley and Ernst, 2004; Kronenberg and Fugh-Berman, 2002; Lethaby et al., 2007; Nelson et 
al., 2006; Tempfer et al., 2007) and 39 human intervention studies which addressed the effect of soy 
isoflavone consumption on vasomotor symptoms associated with menopause were provided either 
separately in the consolidated list or in the systematic reviews/meta-analyses provided.  
Two of the studies provided were open-label, one-arm, uncontrolled human interventions in 
190 (Albert et al., 2002) and 169 (Drews et al., 2007) post-menopausal women, respectively. The 
Panel considers that no conclusions can be drawn from these uncontrolled studies for the scientific 
substantiation of the claim. Some RCTs included women with a diagnosis of breast cancer and/or on 
tamoxifen therapy (MacGregor et al., 2005; Nikander et al., 2003; Petri Nahas et al., 2004; Quella et 
al., 2000; Secreto et al., 2004; Van Patten et al., 2002). In one study, tamoxifen use was not an 
exclusion criterion, and the number of women recruited who were on tamoxifen (if any) was not 
reported (Albertazzi et al., 1998). The Panel notes that no evidence has been provided that women 
with breast cancer and/or on tamoxifen therapy are representative of the target population with respect 
to the frequency and/or severity of hot flushes and night sweats, or that results obtained in women 
with breast cancer and/or on tamoxifen therapy can be extrapolated to menopausal women in the 
general population. In one study, hormone replacement therapy (HRT), which could have an impact 
on the claimed effect, was started by some of the subjects during the study (Burke et al., 2003) and in 
one study (Penotti et al., 2003) the use of HRT or other medication was not reported to be an 
exclusion criterion, and the number of women (if any) recruited who were on HRT or on other 
medication which could have an effect on vasomotor symptoms was not reported. In another study 
(Lewis et al., 2006), some of the subjects took, throughout the study, medication such as Cimicifuga 
racemosa (L.) Nutt. or therapy for thyroid disease, which could have had an impact on the claimed 
effect, or during the study started antibiotic therapy which had been defined as an exclusion criterion 
for the study. In three of the studies (Colacurci et al., 2004; Washburn et al., 1999; Welty et al., 
2007a) subjects were not appropriately blinded to the intervention (i.e. the effects of soy isoflavones 
in various forms were compared to no treatment, or the control and intervention were not consumed at 
the same daily frequency). The Panel notes that successful blinding of subjects is particularly 
important to evaluate self-reported health outcomes, such as frequency and severity of hot flushes, for 
which a high placebo effect can be expected. The description of the methods used for statistical 
analyses was not provided in two studies (Caserta et al., 2005; Uesugi et al., 2004), one study did not 
report on the amount of isoflavones used (Murkies et al., 1995), two studies did not report on 
vasomotor symptoms specifically but on scores for menopausal symptoms combined using the 
Kupperman Index (Sammartino et al., 2003), or on general quality of life questionnaires (Kok et al., 
2005), and one study used the Menopause-Specific Quality of Life Questionnaire, which only 
provides information about the occurrence and degree of bother caused by menopausal symptoms, 
including vasomotor symptoms, but not on their frequency or severity (Basaria et al., 2009). In one 
cross-over study only within-treatment, but no between-treatment, comparisons were reported (Dalais 
et al., 1998), in one study randomisation did not take into account the pre-planned sub-group analysis 
of equol and non-equol producing subjects, and no overall results were reported (Jou et al., 2008), and 
in a further study in which the presence of menopausal symptoms was not an inclusion criterion, no 
information was provided on whether subjects were comparable at baseline with regard to 
menopausal symptoms, and whether the use of HRT or other medication, which could have had an 
impact on the claimed effect, was an exclusion criterion for the study (Scambia et al., 2000). In two 
small sample size studies (Balk et al., 2002; Duffy et al., 2003) the presence of menopausal symptoms 
was not an inclusion criterion, and the sample size of women experiencing menopausal symptoms in 
these studies might have been insufficient to detect a statistically significant difference between the 
intervention and the control, and in one study (Kaari et al., 2006) the effect of soy isoflavones was 
compared to oestrogen therapy but lacked a negative control. The Panel considers that no conclusions 
can be drawn from these references for the scientific substantiation of the claim.  
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In the meta-analysis by Howes et al. (2006), four electronic databases were searched (time span of 
search not reported) for parallel design RCTs of at least four weeks which compared an isoflavone 
intervention to a non-isoflavone, non-oestrogenic control, and reported the frequency and variance of 
hot flushes. Twelve studies on soy isoflavones met the inclusion criteria (Albertazzi et al., 1998; 
Burke et al., 2003; Colacurci et al., 2004; Faure et al., 2002; Han et al., 2002; Knight et al., 2001; 
Murkies et al., 1995; Penotti et al., 2003; Scambia et al., 2000; St Germain et al., 2001; Upmalis et al., 
2000; Van Patten et al., 2002). The Panel notes that study quality was not assessed in this 
meta-analysis and that some of the studies included did not allow conclusions to be drawn on the 
effects of isoflavones on the frequency of hot flushes owing to the following limitations: inclusion of 
women with breast cancer on tamoxifen (Van Patten et al., 2002), uncertainty as to whether women 
were on tamoxifen (Albertazzi et al., 1998), uncertainty as to whether subjects were blinded to the 
intervention (Colacurci et al., 2004), uncertainty on the amount of isoflavones provided (Murkies et 
al., 1995), and uncertainty as to comparability at baseline in the study groups (Scambia et al., 2000). 
The Panel considers that no conclusions can be drawn from these studies, and thus from the 
meta-analysis for the scientific substantiation of the claim.  
In the meta-analysis by Nelson et al. (2006), several databases were searched up to October 2005 for 
RCTs in English on the effect of non-hormonal therapies on the frequency and severity of hot flushes. 
In addition, systematic reviews were hand searched. Eleven trials on soy isoflavone extracts met the 
inclusion criteria. Trials were included if they measured frequency or severity of hot flushes. 
Six (Crisafulli et al., 2004; Faure et al., 2002; Penotti et al., 2003; Quella et al., 2000; Scambia et al., 
2000; Upmalis et al., 2000) out of the 11 trials provided data for a meta-analysis. The Panel notes that 
this meta-analysis included a study in patients with breast cancer on tamoxifen medication (Quella et 
al., 2000), as well as a trial considered by the authors as being of poor quality (Scambia et al., 2000). 
Results were reported overall and excluding either the study in breast cancer patients or the poor 
quality trial, but not excluding both. The Panel considers that no conclusions can be drawn from this 
meta-analysis for the scientific substantiation of the claim.  
From the remaining human intervention studies provided, either separately in the consolidated list or 
in the systematic reviews, seven investigated the effect of soy isoflavones on both frequency and 
severity of hot flushes (Albertazzi et al., 2005; D'Anna et al., 2007; Khaodhiar et al., 2008; Knight et 
al., 2001; Nahas et al., 2007; St Germain et al., 2001; Upmalis et al., 2000), two investigated 
frequency only (Crisafulli et al., 2004; Faure et al., 2002) and three severity only (Cheng et al., 2007; 
Han et al., 2002; Kotsopoulos et al., 2000). Three of these studies also investigated the effect of soy 
isoflavones on night sweats (Cheng et al., 2007; St Germain et al., 2001; Upmalis et al., 2000). In all 
of these studies, subjects in the intervention and control groups within these studies were not different 
at baseline with regard to the frequency and/or severity of hot flushes and/or night sweats. 
In eight out of nine studies which investigated the effect of soy isoflavones on the frequency of hot 
flushes, frequency of hot flushes was self-assessed in symptom diaries or cards, in which the daily 
symptoms were noted, while in the remaining study by St Germain et al. (2001) this outcome was 
assessed by an interviewer-administered menopausal index. In the 10 studies which investigated the 
effect of soy isoflavones on severity of hot flushes, severity of hot flushes was assessed by self-rating 
scales in five studies (Cheng et al., 2007; D'Anna et al., 2007; Khaodhiar et al., 2008; Nahas et al., 
2007; Upmalis et al., 2000), by the vasomotor sub-scale of the Greene Climacteric Scale in two 
studies (Albertazzi et al., 2005; Knight et al., 2001), by the vasomotor symptom score of the 
Kupperman Index in one study (Han et al., 2002), by an interviewer-administered menopausal index 
in one study (St Germain et al., 2001), and by a validated questionnaire in the remaining study 
(Kotsopoulos et al., 2000). In the three of the aforementioned studies which investigated night sweats, 
one study (Cheng et al., 2007) assessed the severity of night sweats only, one study (Upmalis et al., 
2000) assessed the frequency of night sweats only, while St Germain et al. (2001) assessed both of 
these measures of night sweats. 
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In the double-blind, randomised cross-over study by Albertazzi et al. (2005), 100 post-menopausal 
women (44-65 years) were allocated to consume daily 90 mg genistein and placebo for six weeks each 
without a wash-out period in between; the cross-over design had not been pre-planned. Subjects had a 
mean hot flush score (frequency x severity) of 7 at baseline, but the study also included subjects who 
were not experiencing any symptoms. The primary endpoint of the study was markers of bone 
turnover. One subject dropped out in the placebo group. Statistical analysis was adjusted for sequence 
and time to exclude a carry-over and a period effect. Frequency and severity of hot flushes were not 
significantly different between the genistein and the placebo periods. Subjects with a hot flush 
score >9 were analysed in a post-hoc analysis (n=41). The Panel notes that this sub-group analysis 
was not pre-planned, and considers that no conclusions can be drawn from the sub-group analysis for 
the scientific substantiation of the claim. The Panel also notes that not all subjects included in the 
study were experiencing vasomotor symptoms, and that the overall results of this study do not show 
an effect of genistein on the frequency or severity of hot flushes. 
In the double-blind, randomised, placebo-controlled study by Khaodhiar et al. (2008) 
191 post-menopausal women (aged 38-60 years) experiencing at least four hot flushes (mean 
frequency: approx. 8, mean severity approx. 2.1 on a 4-point scale) per day were randomised to 
consume daily either 40 mg daidzein-rich isoflavone aglycones (DRI) (n=48 analysed), 60 mg DRI 
(n=49 analysed) or placebo (n=45 analysed) in capsule form for 13 weeks. It was calculated that 
50 women per group would be needed to detect with an 80 % power an average difference between 
groups of 1.2 hot flushes per day and a hot flush score (frequency x severity) of three units per day 
with a 0.58 SD and a p-value <0.05. Forty-nine subjects did not complete the study (group not 
reported) and were not taken into account in the analysis. Hot flush frequency and severity was not 
significantly different between the 40 mg or 60 mg DRI groups compared to placebo at any time point 
(4, 8 and 12 weeks). In a post-hoc analysis, data from week 12 from both DRI groups were pooled 
together and compared to placebo. The Panel notes that the data pooling was not pre-planned, and 
considers that no conclusions can be drawn from this post-hoc analysis for the scientific 
substantiation of the claim. The Panel also notes the high drop-out rate, that missing data were not 
taken into account in the analysis, and that the primary analysis of this study does not show an effect 
of daidzein-rich isoflavone aglycones on the frequency or severity of hot flushes.  
In the double-blind, randomised, placebo-controlled trial by Kotsopoulos et al. (2000), 
94 post-menopausal women (mean age 59.5 years) of whom 80 % were experiencing menopausal 
symptoms (not different between groups, mean symptom score approx. 0.8 on a 3-point scale) were 
randomised to consume either 118 mg isoflavones in soy powder (n=44) or casein powder (n=50) 
twice daily in sachet form taken in the form of beverages for 12 weeks. Nineteen subjects withdrew 
from the study (10 in the soy and 9 in the placebo group), and a further two in the soy group were not 
taken into account in the analysis (n=32 analysed in the soy group and n=41 analysed in the placebo 
group). No statistically significant differences were observed between the intervention and control 
group with respect to vasomotor symptom scores at 12 weeks. No other time points were measured. 
The Panel notes that missing data were not taken into account in the analysis and that this study does 
not show an effect of soy isoflavones on the severity of hot flushes. 
In a double-blind, randomised, controlled, multicentre study, 75 post-menopausal women (mean age: 
53 years) with at least seven hot flushes (including night sweats) per day (mean frequency: 10) during 
a 2-week pre-study period were allocated to consume daily for 16 weeks either 70 mg soy isoflavones 
in the form of a soy extract (n=39) or placebo (n=36, microcrystalline cellulose and magnesium 
stearate) (Faure et al., 2002). A sample size of 30 subjects per arm was required to detect, with 90 % 
power, a difference of three hot flushes per 24 hours, assuming an SD of 3.8 with a p<0.05. The 
primary endpoint of the study was the number of daily moderate to severe hot flushes (including night 
sweats) in each month of treatment. Six subjects dropped out in the soy group, and 14 in the placebo 
group. Data analysis was reported to have been performed per protocol, and as “last observation 
carried forward”. The Panel notes that carrying forward the last observation is not an appropriate 
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method of taking into account missing data. Per protocol/completer analysis did not show a 
statistically significant difference between the soy and placebo groups in numbers of moderate to 
severe hot flushes. The Panel notes the high drop-out rate, and that the primary analysis of this study 
does not show an effect of soy isoflavones on the frequency of hot flushes. 
In the double-blind, placebo-controlled intervention by St Germain et al. (2001), 69 peri-menopausal 
women (aged 42-62 years) who were experiencing at least 10 vasomotor symptoms per week (mean 
frequency and severity not reported) received either isolated soy protein containing 80.4 mg/day 
isoflavone aglycone components (ISP
+
, n=24), 4.4 mg/day isoflavone aglycone components (ISP
-
, 
n=24) or control (whey protein, n=21) in the form of muffins and soy or placebo powder as meal 
replacements for 24 weeks in four different cohorts in which the interventions were equally 
represented. One control subject was not included in the analysis. No statistically significant effect of 
soy isoflavones on the reduction of frequency or severity of hot flushes and night sweats between 
groups was found at any time point (12 and 24 weeks). The Panel notes the lack of power 
calculations, and that this study does not show an effect of soy isoflavones on the frequency or 
severity of hot flushes or night sweats. 
In the double-blind, randomised, placebo-controlled trial by Knight et al. (2001), 24 post-menopausal 
women (40-65 years) with at least three hot flushes (mean frequency: approx. 7.5, mean severity not 
reported) per day were randomised to receive either 134.4 mg soy isoflavones (containing 77.4 mg of 
aglycones) in 60 g soy powder (n=12) or casein powder (n=12) once daily in sachet form (to be 
consumed as beverages) for 12 weeks. Three women in the intervention group and one in the placebo 
group withdrew from the study. Analyses were reported to have been performed in the 
intention-to-treat population. No statistically significant differences were found between the soy and 
the placebo groups with regard to frequency and severity of hot flushes at 12 weeks. No other time 
points were measured. The Panel notes that no power calculations were performed, and that this study 
does not show an effect of soy isoflavones on the frequency or severity of hot flushes.  
In the double-blind, randomised, controlled, multicentre (15 centres) trial by Upmalis et al. (2000), 
177 post-menopausal women with at least five hot flushes per day (mean frequency: 9, mean 
severity: 2 on a 3-point scale) were randomised to receive daily either 50 mg of soy isoflavones in a 
soy extract in tablet form (n=89) or placebo (not specified, n=86) for 12 weeks. The primary endpoint 
for efficacy was reported to be the reduction of frequency and severity of hot flushes. Data from 
59 subjects in the intervention group and 63 in the placebo group were evaluated for hot flushes and 
night sweats. There was a statistically significant reduction in severity of hot flushes per week 
between the soy and the placebo group at week 12 (approx. -27 % vs. -19 %, p=0.01). There was a 
statistically significant reduction in the frequency of hot flushes and episodes of night sweats (as 
assessed by awakenings during the night) between the soy and the placebo group at week six 
(approx. -27 % vs. -12 %, p=0.02 for hot flushes; approx. -60 % vs. -25 % p<0.04 for night sweats), 
while this difference was not significant at week 12. The Panel notes that missing data were not taken 
into account in the analysis, and that this study shows an effect of soy isoflavones on the severity of 
hot flushes, but that soy isoflavones did not have a sustained effect on the frequency of hot flushes 
and episodes of night sweats. The Panel notes that the results of this study are inconsistent with 
respect to the effect of soy isoflavones in soy protein on vasomotor symptoms. 
In a sub-study of a double-blind, randomised, controlled bone loss trial, D'Anna et al. (2007) analysed 
247 (of 389) post-menopausal women (mean age: approx. 53 years) experiencing hot flushes (mean 
frequency: approx. 4, mean severity: approx. 2.3 on a 3-point scale) who consumed either 27 mg per 
day of genistein (n=125) or placebo (n=122) for 12 months. It was calculated that at least 97 subjects 
per group were needed to detect, with an 80 % power in two-sided tests, a difference of 20 % between 
groups with a p<0.05. Ten subjects dropped out in the genistein group and eight in the placebo group, 
and were not taken into account in the data analysis (n=115 analysed in the genistein group and n=114 
analysed in the placebo group). A statistically significant difference was observed between the 
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genistein and the placebo groups in the frequency of hot flushes per day at 1 month (mean change -1.1 
vs. 0.2, p<0.001), at 3 months (mean change -1.8 vs. 0.5, p<0.001), at 6 months (mean change -2.0 vs. 
0.5, p<0.001) and at 12 months (mean change -2.5 vs. 0; p<0.001), and in severity scores at 1 month 
(mean change -0.3 vs. 0.1, p=0.005), at 3 months (mean change -0.6 vs. 0.1, p<0.001), at 6 months 
(mean change -0.7 vs. 0, p<0.001) and at 12 months (mean change -0.9 vs. -0.1; p<0.001). The Panel 
notes that the study was a sub-analysis of a bone study, and that missing data were not taken into 
account in the analysis. The Panel also notes that this study shows an effect of genistein on the 
frequency and severity of hot flushes. 
In the randomised, placebo-controlled trial by Han et al. (2002), 82 women (aged 45-55 years) who 
were experiencing hot flushes (mean severity score approx. 2.5 on a 3-point scale) were assigned to 
consume daily for four months either 150 mg soy protein and 100 mg soy isoflavones (n=41) or 
150 mg soy protein without isoflavones (n=41). One subject in each group dropped out during the 
study. The vasomotor symptom score of the Kupperman Index significantly decreased in the soy 
isoflavone group compared to the placebo group (mean change -3.1 vs. -0.1; p<0.01) at four months. 
The Panel notes the basic statistical analyses performed, and that this study shows an effect of soy 
isoflavones on the severity of hot flushes.  
In the double-blind, randomised, placebo-controlled study by Nahas et al. (2007), 80 post-menopausal 
women (mean age approx. 55 years) with at least five hot flushes (mean frequency: approx. 10, mean 
severity: approx. 9 on a 12-point scale) per day were allocated to consume daily either 100 mg of 
isoflavones in 250 mg standardised soy extract (n=40) or placebo (lactose; n=40) for ten months. Four 
subjects dropped out during the study (two in the intervention group and two in the placebo group) 
and were not taken into account in the analysis (n=38 analysed in the soy group and n=38 analysed in 
the placebo group). At the end of the study, the mean frequency of hot flushes decreased significantly 
in the soy group as compared to placebo (mean change -6.5 vs. -4.2, p<0.001), as did the hot flush 
severity scores (mean change -6.5 vs. -2.7, p<0.001). Between-group comparisons for other time 
points (4 and 7 months) were not reported. The Panel notes that the statistical analysis was not 
appropriate for the study design, that missing data were not taken into account in the analysis, and that 
this study shows an effect of soy isoflavones on the frequency and severity of hot flushes. 
In the double-blind, placebo-controlled study by Crisafulli et al. (2004), 90 post-menopausal women 
(47-57 years) experiencing a mean of 4.6 hot flushes per day were randomised to receive either HRT 
(n=30), 54 mg genistein per day (n=30) or placebo (n=30) for 12 months. The primary endpoint of the 
study was bone loss. Seven subjects withdrew from taking the intervention or placebo (groups and 
reasons for withdrawal were not reported) but completed the study and were included in the analysis. 
Compared to placebo the number of hot flushes decreased significantly after 3 months (-22 %, 95 % 
-38, -6.2, p<0.01), 6 months (-29 %, 95 % CI -45, -13, p<0.001) and 12 months (-24 %, 95 % CI, -43, 
-5, p<0.01) of genistein consumption. The Panel notes that the description of the statistical methods 
used is insufficient, and that this study shows an effect of genistein on the frequency of hot flushes. 
In the double-blind, randomised placebo-controlled trial by Cheng et al. (2007), 60 post-menopausal 
women (49-69 years) with hot flushes and night sweats (mean hot flush and night sweat scores 
approx. 1.4 on a 5-point scale) were assigned to consume daily either 60 mg isoflavones in a 
fruit-flavoured drink produced from soy beans (n=26 completers) or a fruit-flavoured oat-meal drink 
(n=25 completers) for 12 weeks. Both vasomotor symptom frequency and severity were assessed, but 
results were only reported for severity scores. Data analyses were performed in completers only. At 
week 12, severity scores for hot flushes were statistically significantly different between the soy and 
the placebo group (mean change -0.7 vs. +0.1; p<0.01), while no differences were found in the 
severity scores for night sweats. No other time points were measured. The Panel notes the absence of 
a placebo effect, that missing data were not taken into account in the analysis, and that this study 
shows an effect of soy isoflavones on the severity of hot flushes but not on the severity of night 
sweats. 
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The Panel notes that from the 12 human intervention studies provided from which conclusions can be 
drawn for the scientific substantiation of the claim, most of which have some methodological 
limitations and/or inadequate reporting, five studies (n=498 subjects analysed; range: 25-115 per 
group) with a duration of 12 weeks to 12 months using doses from 27 mg genistein to 100 mg of total 
isoflavones showed a statistically significant effect of soy isoflavones on vasomotor symptoms after 
one month (D'Anna et al., 2007), three months (Cheng et al., 2007; Crisafulli et al., 2004), four 
months (Han et al., 2002) and 10 months (Nahas et al., 2007), whereas six studies (n=463 subjects 
analysed, range: 12-99 per group/period) with a duration of six weeks to six months using doses from 
40 mg to 118 mg of total isoflavones did not show a statistically significant effect of soy isoflavones 
on vasomotor symptoms (Albertazzi et al., 2005; Faure et al., 2002; Khaodhiar et al., 2008; Knight et 
al., 2001; Kotsopoulos et al., 2000; St Germain et al., 2001), and that one study in 122 analysed 
subjects using a dose of 50 mg isoflavones for four months led to inconsistent results with regard to 
the effect soy isoflavones on vasomotor symptoms.   
In weighing the evidence, the Panel took into account that the evidence provided by 12 human 
intervention studies is inconsistent with respect to the reduction of vasomotor symptoms, and that the 
inconsistent results cannot be explained by dose, sample size, study duration, or baseline frequency or 
severity of vasomotor symptoms.  
The Panel concludes that the evidence provided is insufficient to establish a cause and effect 
relationship between the consumption of soy isoflavones and reduction of vasomotor symptoms 
associated with menopause. 
3.4. Contribution to normal hair growth (ID 1704a, 4254) 
Among the references provided were a number of narrative reviews and a textbook which were either 
not related to the claimed effect or did not provide any original data which could be used for the 
scientific substantiation of the claim. Some of the references provided were not related to the food 
constituent, which is the subject of the claim, or investigated the effect of soy isoflavones in 
combination with other substances. A number of human, animal and in vitro studies were not related 
to the claimed effect; these studies included references on the effect of soy isoflavones on symptoms 
associated with the menopause, asthma severity, DNA damage, mood, cognitive function, bone loss, 
blood lipids and cancer. The Panel considers that no conclusions can be drawn from these references 
for the scientific substantiation of the claim.  
An in vitro study assessed the effect of isoflavones on hair growth in cultured human isolated hair 
follicles. The Panel considers that evidence provided in in vitro studies is not sufficient to predict the 
occurrence of an effect of soy isoflavone consumption on hair growth in vivo in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of soy isoflavones and contribution to normal hair growth. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, soy isoflavones, which is the subject of the health claims, is sufficiently 
characterised. 
Protection of DNA, proteins and lipids from oxidative damage (ID 1286, 4245) 
 The claimed effects are “vascular effects including protection from oxidative damage” and 
“antioxidant status”. The target population is assumed to be the general population. Protection 
of DNA, proteins and lipids from oxidative damage may be a beneficial physiological effect. 
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 A cause and effect relationship has not been established between the consumption of soy 
isoflavones and protection of DNA, proteins and lipids from oxidative damage. 
Maintenance of normal blood LDL-cholesterol concentrations (ID 1135, 1704a, 3093a) 
 The claimed effects are “cholesterol management / heart health”, “menopause/skin and hair 
health during menopause/cholesterol management” and “act as phyto-estrogens”. The target 
population is assumed to be the general population. Maintenance of normal blood 
LDL-cholesterol concentrations is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
extracted soy isoflavones and maintenance of normal blood LDL-cholesterol concentrations. 
Reduction of vasomotor symptoms associated with menopause (ID 1654, 1704b, 2140, 3093b, 
3154, 3590) 
 The claimed effects are “menopause”, “menopause/skin and hair health during 
menopause/cholesterol management”, “soy contains the phytoestrogens isoflavones that can 
function as either an estrogen agonist or antagonist”, “act as phytoestrogens”, “helps to keep 
healthy thermoregulation during climacterium”, and “helps to alleviate the symptoms of 
menopause”. The target population is assumed to be post-menopausal women. In the context 
of the proposed wordings and the clarifications provided by Member States, it is assumed that 
the claimed effects refer to the reduction of vasomotor symptoms associated with menopause. 
Reduction of vasomotor symptoms associated with menopause is a beneficial physiological 
effect. 
 The evidence provided is insufficient to establish a cause and effect relationship between the 
consumption of soy isoflavones and reduction of vasomotor symptoms associated with 
menopause. 
Maintenance of normal skin tonicity (ID 1704a) 
 The claimed effect is “menopause/skin and hair health during menopause/cholesterol 
management”. The target population is assumed to be post-menopausal women. In the context 
of the proposed wordings and the clarifications provided by Member States, it is assumed that 
the claimed effect refers to the maintenance of normal skin tonicity. No evidence has been 
provided on how skin tonicity could be related to skin function. 
 The claim does not refer to a function of the body as required by Regulation (EC) No 
1924/2006. 
Contribution to normal hair growth (ID 1704a, 4254) 
 The claimed effect is “menopause/skin and hair health during menopause/cholesterol 
management” and “hair growth and loss”. The target population is assumed to be the general 
population. Contribution to normal hair growth is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of soy 
isoflavones and contribution to normal hair growth. 
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“Cardiovascular health” (ID 3587) 
 The claimed effect is “contributes to cardiovascular health”. The target population is assumed 
to be the general population. The claimed effect has not been sufficiently defined and no 
clarifications were provided by Member States. 
 The claimed effect is general and non-specific, and does not refer to any specific health claim 
as required by Regulation (EC) No 1924/2006. 
Treatment of prostate cancer (ID 3588) 
 The claimed effect is “contributes to maintain a healthy prostate and breast”. The target 
population is assumed to be the general population. From the references provided, it is 
assumed that the claimed effect is related to the treatment of prostate cancer. 
 The claim is related to the treatment of diseases and does not comply with the criteria laid 
down in Regulation (EC) No 1924/2006. 
“Upper respiratory tract” (ID 3589) 
 The claimed effect is “contributes to the upper respiratory tract health”. The target population 
is assumed to be the general population. The claimed effect has not been sufficiently defined 
in the information provided. 
 The claimed effect is general and non-specific, and does not refer to any specific health claim 
as required by Regulation (EC) No 1924/2006. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1874, 
EFSA-Q-2008-2024, EFSA-Q-2008-2390, EFSA-Q-2008-2440, EFSA-Q-2008-2873, EFSA-Q-2008-
3825, EFSA-Q-2008-3886, EFSA-Q-2008-4312, EFSA-Q-2008-4313, EFSA-Q-2008-4314, EFSA-Q-
2008-4315, EFSA-Q-2008-4955, EFSA-Q-2008-4964 , EFSA-Q-2008-05018, EFSA-Q-2008-05019). 
The scientific substantiation is based on the information provided by the Member States in the 
consolidated list of Article 13 health claims and references that EFSA has received from Member 
States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's 
development and health. This Community list shall be adopted through the Regulatory Committee 
procedure and following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food 
many health claims may therefore be scientifically true. Therefore, the relative importance of food 
e.g. nutrients in relation to other nutrients for the expressed beneficial effect should be considered: 
for functions affected by a large number of dietary factors it should be considered whether a 
reference to a single food is scientifically pertinent.  
                                                     
6  OJ L12, 18/01/2007 
7  The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8  The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. 
Claims should be scientifically substantiated by taking into account the totality of the available 
scientific data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and 
the claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of 
the target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional 
or physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment 
whether such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between 
the food and the function. This may be due to commercial practices, consumer perception and 
linguistic or cultural differences across the EU. Nevertheless, the wording used to make health 
claims should be truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 
3 and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient 
or other substance in growth, development and the functions of the body". Therefore, the 
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requirement to describe or refer to the 'role' of a nutrient or substance in growth, development and 
the functions of the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different 
relationships between the various foods and health. It is not the intention of the regulator to adopt a 
detailed and rigid list of claims where all possible wordings for the different claims are approved. 
Therefore, it is not required that EFSA comments on each individual wording for each claim unless 
the wording is strictly pertinent to a specific claim. It would be appreciated though that EFSA may 
consider and comment generally on such elements relating to wording to ensure the compliance with 
the criteria laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific 
data, and by weighing the evidence. In this context EFSA is invited to comment on the 
nature and quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
Soy isoflavones related health claims 
 
38 EFSA Journal 2011;9(7):2264 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and 
the claimed effect in humans and whether the magnitude of the effect is related to the 
quantity consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of 
a balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the 
marketing of the food/food constituent, a positive assessment of its safety, nor a decision on whether 
the food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an 
assessment is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions 
of use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to soy isoflavones, including conditions of use from 
similar claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
1135 Soya (Glycine max [L.] 
Merr.) 
Cholesterol management / 
heart health 
Inclusion of at least 25g [or 40-
90 mg soy isoflavones] soya 
protein per day as part of a diet 
low in saturated fat promotes 
heart health / helps control 
blood cholesterol. 
Conditions of use 
 Consumption of at least 25 g of soya protein (or 40-90 mg soy isoflavones) a day, as part 
of an overall diet low in saturated fat 
 25 g soy protein per day 
 Must be at least a source of protein as per Annex Regulation 1924/2006, 25g soya protein 
per day 
 Must include a statement to the affect that at least 25g of soya protein per day must be 
consumed as part of a diet low in saturated fat. Products carrying this claim should: i) Not 
imply that consumption of more, or less, than 25g per day is advantageous. ii) Not imply 
that consumption of 25g soya protein per day is a dietary requirement. iii) Contain a 
minimum of 5g* of soya protein per serving (*Amended 260903). iv) State what 
constitutes a serving and the amount of soya protein provided in each serving expressed 
as grams or millilitres, e.g. „One 200ml glass‟; „One 125g pot‟ etc. v) State the proportion 
(i.e. a „fifth‟, „quarter‟, „third‟, „half‟ etc) of the 25g daily intake in each serving, e.g. „A 
100g serving contains 8.34g of soya protein, which is one third of 25g‟. vi) The claim 
relates to soya protein that has retained its naturally occurring isoflavones 
ID Food or Food constituent Health Relationship Proposed wording 
1286 Soy Vascular effects including 
protection from oxidative 
damage 
-soy offers specific vascular 
benefits; '-soy helps keep the 
arteries healthy and helps keep 
a healthy heart; -soy helps 
protect the body tissues and 
cells from oxidation oxidative 
damage. 
Conditions of use 
 1-2 servings per day (40mg of isoflavones) 
 Intake of 45 mg isoflavones (aglycone equivalent) per day 
ID Food or Food constituent Health Relationship Proposed wording 
1654 Soy Isoflavones 
 
Menopause 
 
Helps to maintain a calm and 
comfortable menopause /helps 
women coping with the telltale 
signs associated with 
menopause, such as hot 
flushes, sweating, restlessness 
and irritability 
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 Conditions of use 
 Products with 80-150mg/100g, 25-50mg/dose of soy isoflavones. The quality and amount 
of the lactic acid in the gut‟s microbial flora affect the usefulness of isoflavones and 
lignan. Isoflavones/dose: 25–50 mg  Isoflavones/day (2 doses): 50–100 mg. 
 Max 80 mg per day 
 Minimum 35 mg per day; 
 35 to 100 mg of soy isoflavones per day 
 50 mg pro Tag 
 100 mg täglich–Nahrungsergänzung 
 > 40 mg/d–Erst bei Dosierungen von 40 mg/d und darüber von Genistein und Daidzein 
oder deren Vorläufermolekülen Biochanin A und Formononetin wurden klinische Effekte 
nachgewiesen. 
 Frauen ab 40 ––Standardisierter Extrakt aus Sojakeimen––40mg isoflavone je 
Einzeldosis––Täglich– 
 Frauen ab 40 –Täglich– 
 60 mg/d 
 50 mg / jour 
ID Food or Food constituent Health Relationship Proposed wording 
1704 Soy Isoflavones Attività estrogenica. 
Rinnovamento cutaneo 
Clarification provided 
Menopause/ Skin and hair 
health during 
menopause/'Cholesterol 
management 
 
Possono aiutare i capelli della 
donna in un periodo di 
naturale cambiamento come il 
climaterio e la menopausa. 
Utili per la tonicità della pelle. 
Per il benessere della donna in 
età menopausale. . Può aiutare 
a mantenere i fisiologici livelli 
di colesterolo. 
Clarification provided 
Soy Isoflavones are 
phytoestrogens that may 
improve skin tonicity and  
decrease hair loss during 
menopause.Soy Isoflavones 
decreases  blood cholesterol 
levels.  
Conditions of use 
 80 mg per day 
 Soya extract rich in isoflavones At least 20 mg isoflavones per day 
ID Food or Food constituent Health Relationship Proposed wording 
2140 Soy Glycine max 
 
Soy contains the 
phytoestrogens isoflavones 
that can function as either an 
estrogen agonist or 
antagonist 
Soy helps maintain well-being 
during menopause Soy can 
positively affect the well-being 
during menopause  
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Clarification provided 
Soy reduces discomfort 
related to menopause 
Conditions of use 
 Extract equal to 40 mg isoflavones/day 
ID Food or Food constituent Health Relationship Proposed wording 
3093 Soya Isoflavones 
 
Act as phyto-estrogens 
Clarification provided 
Helps maintain normal 
cholesterol Menopause: 
Necessary for a calm and 
comfortable menopause. 
Helps women coping with 
the teltale signsassociated 
with menopause, such as hot 
flushes, sweating, 
restlessness and irritablity. 
Soya isoflavones act as/are 
phyto-estrogens. Contains 
phytoestrogens Added 
goodness of soya isoflavones, 
which act as phytoestrogens. 
Added goodness of soya 
phytoestrogens Contains soya 
isoflavones, which act as 
phytoestrogens  
Conditions of use 
 20mg isoflavones per serving 
ID Food or Food constituent Health Relationship Proposed wording 
3154 isoflavones 
 
helps to keep healthy 
termoregulation during 
climacterium 
helps to reduce untoward 
effects of climacterium e.g. 
hot flush, exudation, strong 
heartbeat 
 Conditions of use 
 50 mg of isoflavones per day 
ID Food or Food constituent Health Relationship Proposed wording 
3587 SOIA ISOFLAVONI Contributes to cardiovascular 
health 
Contributes to cardiovascular 
health 
Conditions of use 
 Dried extract (tit. total isoflavons 40%): 0.8-1 mg/kg/day, divided in 2-3- doses with 
empty stomach 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
3588 SOIA ISOFLAVONI Contributes to maintain a 
healthy prostate and breast. 
 
Clarification provided 
Acting as phytoestrogenes  
decrease the effects due to 
levels of sexual hormones in 
the blood. 
Useful for normal prostate 
function.  
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Conditions of use 
 Dried extract (tit. total isoflavons 40%): 0.8-1 mg/kg/day, divided in 2-3- doses with 
empty stomach 
ID Food or Food constituent Health Relationship Proposed wording 
3589 SOIA ISOFLAVONI Contributes to the upper 
respiratory tract health 
Balm: due to its balsamic 
activity could help during the 
cool season. 
Conditions of use 
 Dried extract (tit. total isoflavons 40%): 0.8-1 mg/kg/day, divided in 2-3- doses with 
empty stomach 
No clarification provided by Member States  
ID Food or Food constituent Health Relationship Proposed wording 
3590 SOIA ISOFLAVONI Helps to alleviate the 
symptoms of menopause 
Contributes to the female 
hormonal balance during 
clymaterium. Helps in case of 
augmented request of 
nutrients. 
 Conditions of use 
 Dried extract (tit. total isoflavons 40%): 0.8-1 mg/kg/day, divided in 2-3- doses with 
empty stomach 
 No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
4245 soyfoods (isoflavones) Antioxidant status Soyfoods naturally contain 
antioxidants (isoflavones) 
which help the body to fight 
free radicals. 
Conditions of use 
 Intake of 45 mg isoflavones (aglycone equivalent) per day 
ID Food or Food constituent Health Relationship Proposed wording 
4254 Dry isoflavones soya 
extract 
Hair growth and loss Act on hair bulb in order to 
support hair growth. Prevent 
hair from premature ageing via 
their antioxidant properties 
and on the microcirculation. 
Conditions of use 
 20 mg per day 
No clarification provided by Member States 
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GLOSSARY AND ABBREVIATIONS 
8-epi-PGF2α 8-epiprostaglandin F2α 
DNA Deoxyribonucleic acid 
DRI Daidzein-rich isoflavone aglycones 
HDL High-density lipoprotein 
HPLC High-performance liquid chromatography 
ISP Isolated soy protein 
IU International Unit 
LDL Low-density lipoprotein 
MDA Malondialdehyde 
NCEP National Cholesterol Education Program 
RCT Randomised controlled trial 
ROS Reactive oxygen species 
TAS Total antioxidant status 
